Bioassay to support clinicians in the determination of the optimal combination/posology of immunosuppressant drugs.biology-220005_1280

In vitro system based on patient´s immune cells to assist the selection of the best immunosuppression regimen for each patient, reducing risk of rejection and IMS side effects in a balanced manner.

  • This model identifies drugs/doses/combined-therapies most able to damper the effector immune response and lymphocyte proliferation which causes rejection.
  • This bioassay intends to help select the best personalized IMs therapy to keep the correct balance between rejection and IMs adverse events.
  • It is a specific 3D cell culture such that enables a sensitive evaluation of IMs performance over patient´s immune cells proliferation and functioning.
  • European patent has been presented in August 2016.